Repository logo

Negative feedback via RSK modulates Erk-dependent progression from naïve pluripotency.

Published version



Change log


Nett, Isabelle Re 
Gatto, Laurent 
Lilley, Kathryn S 


Mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signalling is implicated in initiation of embryonic stem (ES) cell differentiation. The pathway is subject to complex feedback regulation. Here, we examined the ERK-responsive phosphoproteome in ES cells and identified the negative regulator RSK1 as a prominent target. We used CRISPR/Cas9 to create combinatorial mutations in RSK family genes. Genotypes that included homozygous null mutations in Rps6ka1, encoding RSK1, resulted in elevated ERK phosphorylation. These RSK-depleted ES cells exhibit altered kinetics of transition into differentiation, with accelerated downregulation of naïve pluripotency factors, precocious expression of transitional epiblast markers and early onset of lineage specification. We further show that chemical inhibition of RSK increases ERK phosphorylation and expedites ES cell transition without compromising multilineage potential. These findings demonstrate that the ERK activation profile influences the dynamics of pluripotency progression and highlight the role of signalling feedback in temporal control of cell state transitions.



RSK, embryonic stem cells, mitogen‐activated protein kinase, pluripotency, signalling feedback, Animals, Cell Differentiation, Cell Lineage, Embryonic Stem Cells, Extracellular Signal-Regulated MAP Kinases, Feedback, Physiological, Humans, Mutation, Phosphoproteins, Phosphorylation, Pluripotent Stem Cells, Proteome, Ribosomal Protein S6 Kinases, 90-kDa, Small Molecule Libraries

Journal Title


Conference Name

Journal ISSN


Volume Title



Springer Science and Business Media LLC
European Commission (242129)
Leverhulme Trust (RPG-2016-418)
European Commission (200720)
This research was funded by European Commission Projects EuroSyStem (HEALTH-F4-2008-200720) and SyBoss (242129) and the Leverhulme Trust (RPG-2016-418). The Cambridge Stem Cell Institute receives core funding from The Wellcome Trust and The Medical Research Council. AS is a Medical Research Council Professor.